Charlotte Parsons
Family · Bremerton, WANPI 1346591500
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,445 of the $13,335 with a category attached, or 63.3%. Dexcom, Inc. accounts for 96.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $5,070 and has fallen 97.3% since, to $138 in 2025. Among family clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 59 payments — averaging $226.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$13K
- Ascensia Diabetes Care US Inc.$86
- Tandem Diabetes Care, Inc.$76
- Medtronic$58
- Lilly USA, LLC$56
- Abbott$47
- plus $98 from 5 others
What the payments were for
- Consulting fees$9007%
- Speaking & faculty fees$8,44563%
- Travel & lodging$2,51819%
- Food & beverage$1,47211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 39 | $12,914 |
| Ascensia Diabetes Care US Inc. | 2 | $86 |
| Tandem Diabetes Care, Inc. | 6 | $76 |
| Medtronic | 2 | $58 |
| Lilly USA, LLC | 3 | $56 |
| Abbott | 2 | $47 |
| Sanofi-aventis U.S. LLC | 1 | $34 |
| Mannkind Corporation | 1 | $20 |
| BETA Bionics, Inc. | 1 | $18 |
| Sequel Med Tech, LLC | 1 | $17 |
| Cequr Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$7,385
- DEXCOM G7 GSS (161)$4,689
How this compares
$13,335 in reported general payments places this provider in the 95th percentile of 1,706 family providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 257 | $327,094 |
| MounjaroTirzepatide | 235 | $323,451 |
| TrulicityDulaglutide | 154 | $241,215 |
| OzempicSemaglutide | 114 | $185,454 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 108 | $157,937 |
| Humalog Kwikpen U-200Insulin Lispro | 26 | $104,101 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $32,367 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $32,364 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $27,672 |
| FarxigaDapagliflozin Propanediol | 24 | $26,977 |
| HumalogInsulin Lispro | 81 | $25,372 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 59 | $24,553 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 154 | $23,157 |
| Humulin R U-500Insulin Regular, Human | 15 | $22,162 |
| Humalog Kwikpen U-100Insulin Lispro | 80 | $21,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $56 | $596,384542 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,706 family providers in Washington.
Other family in Bremerton
- Sherri ZumdieckBremerton$9K
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
- Hye-Jin GehringBellevue$30K
- Kaitlin BrasierSeattle$29K
- Karen JohnsonSeattle$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.